Oral PUVA and topical steroids for treatment of oral manifestation of chronic graft-vs.-host disease

Photodermatology Photoimmunology and Photomedicine

Volumn 20, Issue 4, 2004, Pages 184-190

  Wolff, Daniel ^a   Anders, V ^b   Corio, R ^c   Horn, T ^c   Morison, W L ^c   Farmer, E ^d   Vogelsang, G B ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Chronic GVHD; Oral mucosa; PUVA; Topical steroids

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DEXAMETHASONE; ETOPOSIDE; GLASS FIBER; METHOXSALEN; NYSTATIN; PENICILLIN G; PREDNISONE; STEROID; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CATARACT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG USE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; MOUTH DISEASE; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHOTOTOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; SIDE EFFECT; TREATMENT FAILURE; ULTRAVIOLET A RADIATION; WHOLE BODY RADIATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; PUVA THERAPY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 4043072067     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2004.00102.x     Document Type: Article

References (39)

1. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-vs.-host disease. Blood 2001; 97: 1219-1226.
2. Horn TD, Rest EB, Mirenski Y, Corio RL, Zahurak ML, Vogelsang GB. The significance of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. Arch Dermatol 1995; 131: 964-965.
3. Nagler RM, Nagler A. Major salivary gland involvement in graft-vs.-host disease: considerations related to pathogenesis, the role of cytokines and therapy. Cytokines Cell Mol Ther 1999; 5: 227-232.
4. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB. Weight loss and malnutrition in patients with chronic graft-vs.-host disease. Bone Marrow Transplant 2002; 29: 231-236.
5. Epstein JB, Truelove EL. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82: 532-536.
6. Epstein JB, Nantel S, Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-vs.-host disease. Bone Marrow Transplant 2000; 25: 683-687.
7. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-vs.-host disease or total-body irradiation after bone- marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997; 24: 539-543.
8. Jansen CT, Lehtinen R, Happonen RP, Lehtinen A, Soderlund K. Mouth PUVA: new treatment for recalcitrant oral lichen planus. Photodermatology 1987; 4: 165-166.
9. Menillo SA, Goldberg SL, McKiernan P, Pecora AL. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-vs.-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 807-808.
10. Narwutsch M, Narwutsch M, Dietz H. [Initial results of the long-term effect of PUVA therapy in lichen ruber of the mouth]. Dermatol Monatsschr 1990; 176: 349-355.
11. Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-vs.-host disease. Biol Blood Marrow Transplant 2002; 8: 206-212.
12. Grundmann-Kollmann M, Martin H, Ludwig R, et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft vs. host disease. Transplantation 2002; 74: 1631-1634.
13. Jampel RM, Farmer ER, Vogelsang GB, Wingard J, Santos GW, Morison WL. PUVA therapy for chronic cutaneous graft-vs.-host disease. Arch Dermatol 1991; 127: 1673-1678.
14. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-vs.-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061-1067.
15. Volc-Platzer B, Honigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-vs.-host disease. J Am Acad Dermatol 1990; 23: 220-228.
16. Leiter U, Kaskel P, Krahn G, et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft vs. host disease. Photodermatol Photoimmunol Photomed 2002; 18: 183-190.
17. Biagi E, Perseghin P, Buscemi F, Dassi M, Rovelli A, Balduzzi A. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft-vs.-host disease. Haematologica 2000; 85: 329-330.
18. Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998; 4: 27-37.
19. Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs. salivary gland changes in lip biopsies in the diagnosis of chronic graft-vs.-host disease. Arch Pathol Lab Med 1989; 113: 932-934.
20. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-vs.-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
21. Glazier A, Morison WL, Bucana C, Hess AD, Tutschka J. Suppression of epidermal graft-vs.-host disease with ultraviolet radiation. Transplantation 1984; 37: 211-213.
22. Kuusilehto A, Happonen RP, Peltola J, Lehtinen R, Jansen CT. The effect of PUVA on Langerhans cells in rat oral epithelium photosensitized with systemic methoxsalen or topical trioxsalen. Photodermatol Photoimmunol Photomed 2000; 16: 129-133.
23. Bredberg A, Forsgren A. Effects of in vitro PUVA on human leukocyte function. Br J Dermatol 1984; 111: 159-168.
24. Neuner P, Charvat B, Knobler R, et al. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochem Photobiol 1994; 59: 182-188.
25. Okamoto H, Takigawa M, Horio T. Alteration of lymphocyte functions by 8-methoxypsoralen and longwave ultraviolet radiation. I. Suppressive effects of PUVA on T-lymphocyte migration in vitro. J Invest Dermatol 1985; 84: 203-205.
26. Okamoto H, Horio T, Maeda M. Alteration of lymphocyte functions by 8-methoxypsoralen and long-wave ultraviolet radiation. II. The effect of in vivo PUVA on IL-2 production. J Invest Dermatol 1987; 89: 24-26.
27. Norris DA, Lyons MB, Middleton MH, Yohn JJ, Kashihara-Sawami M. Ultraviolet radiation can either suppress or induce expression of intercellular adhesion molecule 1 (ICAM-1) on the surface of cultured human keratinocytes. J Invest Dermatol 1990; 95: 132-138.
28. Simon JC, Cruz PD Jr, Bergstresser PR, Tigelaar RE. Low dose uitraviolet B-irradiated Langerhans cells preferentially activate CD4 + cells of the T helper 2 subset. J Immunol 1990; 145:2087-2091.
29. Simon JC, Tigelaar RE, Bergstresser PR, Edelbaum D, Cruz PD Jr. Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. Induction of specific clonal anergy in CD4+ T helper 1 cells. J Immunol 1991; 146: 485-491.
30. Stingl LA, Sauder DN, Iijima M, Wolff K, Pehamberger H, Stingl G. Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol 1983; 130: 1586-1591.
31. Tokura Y, Yagi J, Edelson RL, Gasparro FP. Inhibitory effect of 8-methoxypsoralen plus ultraviolet-A on interleukin-1 production by murine keratinocytes. Photochem Photobiol 1991; 53: 517-523.
32. Ashworth J, Kahan MC, Breathnach SM. PUVA therapy decreases HLA-DR+ CDIa+ Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR+ CDIa+ Langerhans cells exhibit normal alloantigen-presenting function. Br J Dermatol 1989; 120: 329-339.
33. Hann SK, Park YK, Im S, Koo SW, Haam IB. The effect on liver transaminases of phototoxic drugs used in systemic photochemotherapy. J Am Acad Dermatol 1992; 26: 646-648.
34. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-93.
35. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-1045.
36. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
37. Gmeinhart B, Hinterberger W, Greinix HT, et al. Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft-vs.-host disease (GVHD). Bone Marrow Transplant 1999; 23: 1197-1199.
38. Otsubo H, Yokoe H, Miya T, et al. Gingival squamous cell carcinoma in a patient with chronic graft-vs.-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 171-174.
39. van der Meij EH, Schepman KP, van dw I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 164-171.